HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report released on Tuesday, Benzinga reports. The firm currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Aprea Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q3 2024 earnings at ($0.56) EPS, […]
Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) – Analysts at Wedbush reduced their FY2028 earnings per share estimates for Aprea Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.77 per share for the year, down from […]
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Aprea Therapeutics (NASDAQ:APRE) Receives "Outperform" Rating from Wedbush dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.